DOCSLIB.ORG

Development of Polymeric Micelles for Site Specific Delivery Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of Polymeric Micelles for Site Specific Delivery Of Development of Polymeric Micelles for Site Specific Delivery of Nonsteroidal Anti-Inflammatory Drugs: Effect on the Cardiovascular Risk in an Experimental Model of Arthritis by Hanan Mustafa Al Lawati A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences Faculty of Pharmacy and Pharmaceutical Sciences University of Alberta © Hanan Mustafa Al Lawati, 2019 Abstract Non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase (COX) enzymes, are among the most widely used medications worldwide with proven efficacy in controlling inflammation and pain associated various disease conditions. The chronic systemic use of most NSAIDs, however, is known to be associated with an increased risk of cardiovascular (CV) events, including myocardial infarction and stroke. Cardiovascular complications associated with the use of NSAIDs are believed to be partly linked to the extent of their exposure to the cardiac tissue among other factors. Research in the field of nanomedicine has shown a remarkable progress in the design of targeted drug delivery systems which can improve drug disposition towards the diseased sites. A systematic search of the scientific literature revealed that reports on the use of such advanced systems for the delivery of NSAIDs that show evidence of improved cardiac safety are lacking. Therefore, in this research work we considered designing nano-formulations for the delivery of diclofenac as a model NSAID for its known serious CV toxicity. The aim was to improve diclofenac pharmacokinetics and biodistribution whereby reducing its accumulation and toxicity in the cardiac tissue. We hypothesize that reduced diclofenac cardiac exposure will lower its CV side effects. Towards this goal, different polymeric micellar formulations based on a shell of poly(ethylene oxide) (PEO) and various hydrophobic polyesters as the hydrophobic core were tried for the encapsulation of diclofenac or its ethyl ester prodrug. The micellar formulations were characterized for size, size distribution, morphology, and in vitro as well as ex vivo drug release. ii The results pointed to the superiority of polymeric micelles with a core of poly(-caprolactone) (PCL) or poly(α-benzyl carboxylate --caprolactone) (PBCL) encapsulating diclofenac ethyl ester as the optimal formulations. In the next step, the biodistribution of the optimal polymeric micellar formulations of diclofenac was investigated in vivo in healthy rats following intravenous (iv) and/or intraperitoneal (ip) administration and compared to that of the free diclofenac. The intravenous administration of the polymeric micellar formulation resulted in prolonged diclofenac systemic circulation and reduced its accumulation in the heart and kidneys compared to the free drug. The polymeric micellar formulations of diclofenac administered through ip route proved to be equally bioavailable as the iv administration. In the following step, multiple dose administration of polymeric micellar formulation of diclofenac in an experimental model of arthritis in rats was employed to assess the anti-inflammatory activity and the safety of the micellar formulation over free drug. To assess the cardiac safety of polymeric micellar formulation versus free drug, the levels of cardioprotective versus cardiotoxic metabolites of arachidonic acid (ArA) was measured in plasma, heart and kidneys following drug administration to these rats with adjuvant arthritis. The results showed that the micellar formulation provided similarly effective therapy for the management of inflammation when compared to the free drug. On the other hand, administration of diclofenac as polymeric micellar formulation reduced the ratio of cardiotoxic over cardioprotective metabolites of ArA in the heart and plasma when compared to the free drug administration. These results provide the first evidence for a potential role in the tissue disposition of diclofenac on its cardiac-safety. It also points to the potential of developed formulations for effective and safe delivery of NSAIDs. iii Preface The following papers are published or considered for publication in refereed journals and are part of the work presented in this thesis: Section 1.5 of chapter 1 is considered for publication as Al-Lawati H., Binkhathlan Z., Lavasanifar A., Nanomedicine for the effective and safe delivery of non-steroidal anti-inflammatory drugs: a review of preclinical research. H. Al Lawati is the lead author and was responsible for identifying and screening relevant reports, analysing the reports, data collection, and composition of the manuscript. Dr. Z. Binkhathlan reviewed the included reports and helped with the article revision. Dr. A. Lavasanifar was the supervisory author and was involved in formulation of concepts, analysis and composition of manuscript. Chapter 2 has been published as Al-Lawati H., Vakili M. R., Jamali F., Lavasanifar A., Polymeric micelles for the delivery of diclofenac and its ethyl ester derivative, Pharmaceutical Nanotechnology 2016; 4(2): 109 – 119. H. Al Lawati is the lead author and was responsible for data collection and analysis as well as for manuscript composition. Dr. M. R. Vakili helped with study design. Dr. F. Jamali and Dr. A. Lavasanifar were the supervisory authors and were involved in formulation of concept, analysis and composition of manuscript. Chapter 3 has been published as Al-Lawati H., Vakili M. R., Lavasanifar A., Ahmed S., Jamali F., Delivery and biodistribution of traceable polymeric micellar diclofenac in the rat, Journal of Pharmaceutical Sciences (in press, appeared online). H. Al Lawati is the lead author and was responsible for data collection and analysis as well as the manuscript composition. Dr. M. R. Vakili helped with study design. S. Ahmed helped with some data acquisition. Dr. A. Lavasanifar and iv Dr. F. Jamali were the supervisory authors and were involved in formulation of concept, analysis and composition of manuscript. Chapter 4 is to be submitted for publication as Al-Lawati H., Vakili M. R., Lavasanifar A., Ahmed S., Jamali F., Pharmacokinetics and pharmacodynamics of traceable polymeric micellar diclofenac in experimental arthritis. H. Al Lawati is the lead author and was responsible for data collection and analysis as well as the manuscript composition. Dr. M. R. Vakili helped with study design. S. Ahmed helped with some data acquisition. Dr. A. Lavasanifar and Dr. F. Jamali were the supervisory authors and were involved in formulation of concept, analysis and composition of manuscript. The supplementary chapter is part of a manuscript to be submitted for publication as Binkhathlan Z., Ali R., Qamar W., Al-Lawati H., and Lavasanifar A. Pharmacokinetic and tissue distribution study of orally administered cyclosporine A-loaded poly(ethylene oxide)-block-poly(ε- caprolactone) micelles versus Sandimmune® in rats. H. Al Lawati was completely responsible for the in vitro and in vivo experiments presented in this thesis in the supplementary chapter. She wrote the methods and results sections related to these experiments in the manuscript and helped with the article revision. Dr. Z. Binkhathlan, Dr. R. Ali, and Dr. W. Qamar were responsible for the other data collection and analysis as well as the manuscript composition. Dr. A. Lavasanifar was the supervisory author and was involved in formulation of concept, analysis and composition of manuscript. In addition, the following refereed journal papers, report research work that was carried out by H. Al Lawati in parallel to the work presented in this thesis and is indirectly related to the thesis: v • Al Lawati H. and Jamali F. Onset of action and efficacy of ibuprofen liquigel as compared to solid tablets: a systematic review and meta-analysis. J Pharm Pharm Sci 2016; 19 (3): 301-311. • Al-Lawati H. Aliabadi H. M., Makhmalzadeh B. S., Lavasanifar, A., Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research. Expert Opin Drug Deliv. 2018 Apr; 15(4):397-418. vi Dedication To my beloved parents Mustafa and Batool for their endless love and support vii Acknowledgments I would like to express my sincere gratitude and appreciation to my supervisor Dr. Fakhreddin Jamali. His encouragement, ideas, continuous help and guidance, interesting courses, and many valuable discussions made this dissertation and my degree possible. I have been fortunate to have had him as my advisor during my studies at the University of Alberta. I would like to also extend my appreciation to my co-supervisor Dr. Afsaneh Lavasanifar for introducing me to the world of nanomedicine and for the many valuable ideas, discussions, suggestions, and for her continuous support and encouragement which made this work possible. I enjoyed working with both Dr. Fakhreddin Jamali and Dr. Afsaneh Lavasanifar on this project. I would like to thank Dr. Raimer Löbenberg and the other members of my thesis committee, Dr. Michael Doschak and Dr. Hasan Uludag, for their valuable comments and suggestions which better shaped this work. Special thanks go to the members of the Dr. Jamali and Dr. Lavasanifar labs, in particular Dr. Mohamed R. Vakili, Dr. Waheed Asghar, Igor Paiva, Nasim Ghasemi, Dr. Forough Sanaee and Surur Ahmed, for their encouragement and help from time to time. I wish them and all my fellow graduate students all the best. A special thanks go to the faculty and staff of the Faculty of Pharmacy and Pharmaceutical Sciences. Above all, I would like to thank my parents
Load more

Recommended publications
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • United States Patent (19) (11) 4,378,354 Ghyczy Et Al
    United States Patent (19) (11) 4,378,354 Ghyczy et al. 45 Mar. 29, 1983 54) NFLAMMATON-PREVENTING 51 Int. Clº. A61K 31/685 PHARMACEUTICAL COMPOSITION OF (52] U.S. Cl. .… 424/199 ORAL ADMINISTRATION 58) Field of Search......................................... 424/199 75) Inventors: Miklos Ghyczy; Adorjan Erdös, both of Cologne; Ginter Heidemann, Primary Examiner-Stanley J. Friedman Geilenkirchen-Tripsrath; Götz Attorney, Agent, or Firm-Burns, Doane, Swecker & Ritzmann, Cologne, all of Fed. Rep. Mathis of Germany 57 ABSTRACT 73) Assignee: A. Nattermann & Cie. GmbH, Cologne, Fed. Rep. of Germany A novel pharmaceutical composition is provided which is suitable for the prevention of inflammation and which (21) Appl. No.: 266,217 comprises non-steroidal inflammation-preventing com 22) Filed: May 22, 1981 pound (e.g. pyrazolones, salicylic acid derivatives, in doles, indanes, and phenylacetic acid and anthranilic Related U.S. Application Data acid derivatives) and at least one phospholipid. 62) Division of Ser. No. 104,449, Dec. 14, 1979, Pat. No. 4,332,795. 17 Claims, No Drawings 4,378,354 2 tic substances can be prevented if these substances are INFLAMMATION-PREVENTING combined in a suitable manner with phospholipids. The PHARMACEUTICAL COMPOSITION OF ORAL medicinal compositions of the present invention will ADMINISTRATION therefore contain these antiphologistic substances in conjunction with phospholipids. The phospholipids This is a division of application Ser. NO. 104,449 filed have the advantage over the previously described sub Dec. 17, 1979 now U.S. Pat. No. 4,332,795. stances in that they are body-inherent, can be readily broken down within the body, do not promote any side BACKGROUND OF THE PRESENT INVENTION effects (even if administered continuously (see J.
    [Show full text]
  • DEPARTMENT of COMMERCE Foreign-Trade
    This document is scheduled to be published in the Federal Register on 08/21/2012 and available online at http://federalregister.gov/a/2012-20547, and on FDsys.gov DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B-64-2012] Foreign-Trade Zone 59 – Lincoln, Nebraska Notification of Proposed Production Activity Novartis Consumer Health, Inc. (Pharmaceutical Products and Related Preparations Production) Lincoln, Nebraska Novartis Consumer Health, Inc. (Novartis) submitted a notification of proposed production activity for the company’s facilities located within Sites 3 and 4 of FTZ 59, in Lincoln, Nebraska. The facilities are used for the production of dosage-form and bulk- quantity mixed medicines, including those containing penicillin, alkaloids, analgesics, antibiotics, antihistamine/decongestants, cold remedies, anti-infectives, dermatological and anesthetic agents, digestive treatments, insulin, vitamins, and hormones; vitamins and provitamins; food preparations, including those containing fiber and various digestive products, lozenges, nicotine gum, and cold symptom products; preparations for skincare; pharmaceutical reference standards; and medicines for veterinary use. Production under FTZ procedures could exempt Novartis from customs duty payments on the foreign-status components used in export production. On its domestic sales, Novartis would be able to choose the duty rates during customs entry procedures that apply to the finished products (mostly duty-free, but some would be up to 6.4 percent for certain food preparations) for
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Chemically Induced Or Drug Induced Tinnitus
    International Tinnitus Journal 2, 1-2 (1996) Chemically Induced or Drug Induced Tinnitus Claus-Frenz Claussen, M.D. Department of Neurootology - University E.N. T Clinic, Wiirzburg, Germany or approaching the truth about the clinical accompanying complaints include hearing disorders and F phenomenon of tinnitus from more and more tinnitus. Many patients complain of reduced hearing and possible aspects, it is important in the sense of understanding of speech. Frequent auditory complaints the old Aristotelean systematics of scientific thinking to include a high pitched noise and a sensation of ear choose various and alternating directions for regarding blockage. Diagnosis is elusive, but is eventually the phenomenon. Therefore, today I am also choosing a established. The neurotoxic complications are increased biochemical angle of view. in number and intensity when solvents are multiple in Our model of good and bad hearing, ear noise or tinnitus, number and are released in combination into the is primarily demonstrated in the dimension of physics environment. CTE is a chronic progressive disease. and modern data technology. Hearing is based on the Recently, a male patient, age 58, was seen in consultation transmission of physical sounds from the surrounding for severe tinnitus. A prior diagnosis of CTE had been world by resonance in space to the outer ear; the physical established 26 years ago, secondary to toxic inhalation amplifier of the middle ear; and finally by digital data of trichlorethylene vapors. Tinnitus was reported to have transmission from the cochlea via the hearing pathways been the initial symptom. The patient discovered the to the temporal lobe of the brain.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Qt3r77r0zg.Pdf
    UCSF UC San Francisco Previously Published Works Title Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome Permalink https://escholarship.org/uc/item/3r77r0zg Journal eNeuro, 2(4) ISSN 2373-2822 Authors Dinday, Matthew T Baraban, Scott C Publication Date 2015-07-01 DOI 10.1523/eneuro.0068-15.2015 Peer reviewed eScholarship.org Powered by the California Digital Library University of California New Research Disorders of the Nervous System Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome1,2,3 Matthew T. Dinday,1 and Scott C. Baraban1,2 DOI:http://dx.doi.org/10.1523/ENEURO.0068-15.2015 1Department of Neurological Surgery, Epilepsy Research Laboratory, University of California San Francisco, San Francisco, California 94143, 2Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143 Abstract Mutations in a voltage-gated sodium channel (SCN1A) result in Dravet Syndrome (DS), a catastrophic childhood epilepsy. Zebrafish with a mutation in scn1Lab recapitulate salient phenotypes associated with DS, including seizures, early fatality, and resistance to antiepileptic drugs. To discover new drug candidates for the treatment of DS, we screened a chemical library of ϳ1000 compounds and identified 4 compounds that rescued the behavioral seizure component, including 1 compound (dimethadione) that suppressed associated electrographic seizure activity. Fenfluramine, but not huperzine A, also showed antiepileptic activity in our zebrafish assays. The effectiveness of compounds that block neuronal calcium current (dimethadione) or enhance serotonin signaling (fenfluramine) in our zebrafish model suggests that these may be important therapeutic targets in patients with DS.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]